Comment: HIV researchers, citizens must be part of decisions

On May 18 1997, United States President Bill Clinton committed to developing an HIV vaccine within 10 years. Nearly 20 years later, we still don’t have one. And every day in South Africa, more than 1 000 people become newly infected. Young women and girls are especially hard-hit by HIV in our country.

But HIV vaccine advocates do have a lot to celebrate with regard to vaccines, and also HIV prevention generally, especially in South Africa.

For much of the first 30 years of the epidemic, there have been essentially two strategies to prevent sexual transmission of HIV: abstinence and condoms.

But in the past decade, we’ve had important advances. For example, we now know that antiretroviral drugs not only keep HIV-positive people healthy, they also work so well that a person on successful HIV treatment has very little chance of passing the virus on to a sexual partner. Treatment is also prevention.

Male circumcision, in which the foreskin of the penis is removed, also works to reduce a man’s risk of acquiring HIV; fewer HIV-positive men mean less HIV risk for women and the population at large. In addition, multiple studies of pre-exposure prophylaxis (PrEP), or preventive treatment – some of them here in South Africa – have shown that men and women at risk of HIV can take a particular type of antiretroviral medication to prevent infection, if they take the pills consistently.


But too many South Africans – especially young girls – don’t realise their risk of HIV, or don’t know what is available to prevent infection. The first step is to give prime-time attention to messages about all these new methods – what they are, how they work, how to get them – and how to know whether you are at risk. For example, a lot more still needs to be understood about how PrEP could be made available in South Africa. At the same time, we need to continue investing in research that will find more and better prevention methods, especially a vaccine.

Vaccine needed to end HIV
An HIV vaccine remains essential to ending the epidemic.

In 2009, in a clinical trial in Thailand, an experimental vaccine showed some success in reducing the risk of HIV transmission.

And earlier this year a trial to test a modified version of that vaccine – redesigned with the goal of making it more protective – started in South Africa. If this trial has positive results, in two years a large-scale efficacy trial would begin, which could eventually lead to a licensed vaccine.

Further upstream, research involves the discovery that some people living with HIV create particularly potent antibodies able to “neutralise” many different HIV strains.

A handful of these “broadly neutralising antibodies”, or bNAbs, have been isolated from blood samples donated by HIV-infected individuals, including women, from a trial here called Caprisa 004. Broadly neutralising antibodies target multiple HIV-1 viral strains and, as opposed to non-bNAbs, are specific to individual viral strains. Scientists are now planning to test whether direct transfer of the most potent antibodies could prevent, treat or even be part of a cure for HIV when infused directly into the bloodstream.

Scientific research, academic meetings and journals have been buzzing with talk about bNAbs for the past few years, especially in the vaccine research community.

But the reality is that bNAb research is in the very early stages, there are many questions and unknowns, and the science is extremely difficult to understand and explain to non-scientists.

Civil society input
As this work moves forward, scientists and funders need to collaborate with advocates and citizens to ensure that adequate resources are allocated to communications and civic engagement.

With all of the excitement about bNAbs and two different vaccine strategies now entering clinical trial phases in Southern Africa, the robust community of African HIV researchers must be at the table before decisions are made.

HIV activists, advocates and community stakeholders who will need to explain the science, purpose and possible outcomes of this research need support to track the research path, ask the hard questions, demand progress and conduct other aspects of the research and development process. Active involvement of our government in driving and funding clinical research also needs close attention.

If the progress we see today is anything to go by, it means we are closer than ever to having an HIV vaccine. But funding is finite and only the most promising strategies should move ahead.

The HIV vaccine field needs to develop a transparent decision-making process that directs efforts towards only the likeliest candidates for success. And that decision-making process must include the people who really need an HIV vaccine.

Ntando Yola is a former HIV Prevention Research Advocacy fellow and works for the Desmond Tutu HIV Foundation in Cape Town

Subscribe to the M&G

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years, and we’ve survived right from day one thanks to the support of readers who value fiercely independent journalism that is beholden to no-one. To help us continue for another 35 future years with the same proud values, please consider taking out a subscription.

Related stories

Stop the ‘war on drugs’, it doesn’t work

Punitive measures simply drive drug use underground. A more effective way is to adopt harm reduction interventions

Six injections a year could stop new HIV infections

New research from seven countries in Africa signals the future of HIV prevention — but what can it learn from its past?

Q&A Sessions: Meet Thembisile Xulu, a doctor, hip-hop fan and mother

Dr Thembisile Xulu, the newly appointed chief executive of the Sanac Trust, tells Nicolene de Wee about a new plan to fight HIV, TB and STIs — and her hip-hop dance moves

“In my heart I scream”: Involve young people in decision-making about their lives

Laws on access to sexual and reproductive health services for adolescents and age of consent to sexual activity in many countries do not adequately serve the needs of young people and even when they are progressive, they are often not well implemented

The high road is in harm reduction

While the restriction of movement curtailed the health services for people who use drugs in some parts of the world, it propelled other countries into finding innovative ways to continue services, a new report reveals

Wheeling and dealing for a Covid-19 vaccine

A Covid-19 jab could cost hundreds of rands. Or not. It’s anyone’s guess. Could another pandemic almost a century ago hold clues for handling the coronavirus today?
Advertising

Subscribers only

Covid-19 surges in the Eastern Cape

With people queuing for services, no water, lax enforcement of mask rules and plenty of partying, the virus is flourishing once again, and a quarter of the growth is in the Eastern Cape

Ace prepares ANC branches for battle

ANC secretary general Ace Magashule is ignoring party policy on corruption-charged officials and taking his battle to branch level, where his ‘slate capture’ strategy is expected to leave Ramaphosa on the ropes

More top stories

Limpopo big-game farmer accused of constant harassment

A family’s struggle against alleged intimidation and failure to act by the authorities mirrors the daily challenges farm dwellers face

Did Botswana execute ‘poachers’ ?

The Botswana Defence Force’s anti-poaching unit has long been accused of a ‘shoot to kill’ policy. Over 20 years the unit has killed 30 Namibians and 22 Zimbabweans

Zondo tightens his grip with criminal complaint against Zuma

The state capture commission’s star witness now faces a criminal complaint and another summons

Sharp sting of the Green Scorpions

Crime busters secure a 97% conviction rate and register more criminal dockets for range of crimes
Advertising

press releases

Loading latest Press Releases…